Studies were conducted to investigate the tissue distribution of stearoyl-CoA desaturase-1 (SCD) and the regulation of SCD1 protein expression by dietary fat, insulin, polyunsaturated fatty acids (PUFA), and linoleic acid (cis-9, cis-12 18:2). The first study examined tissue distribution of SCD1 protein in Holstein calves (n=6/diet) fed one of four milk replacer diets for a nine wk period after which they were sacrificed. Milk replacer diets varied in fat content and were formulated and administered as follows: 0.4 kg/d 20% protein, 20% fat (20:20; CON), 0.97 kg/d (28:20; HPLF), 0.97 kg/d (28:28; HPHF), or 1.46 kg/d (28:28; HPHF+). Samples of subcutaneous adipose tissue (AT), perirenal AT, omental AT, duodenum, proximal jejunum, distal jejunum, ileum, and liver were collected from calves fed the HPHF+ diet to determine SCD1 tissue distribution. Tissue homogenates were prepared and used for Western blotting. Additionally, dietary effects were analyzed on tissues expressing SCD1 protein for all 24 calves. The second study investigated the regulation of SCD1 protein expression by insulin, fatty acids increasing in degree of unsaturation, and increasing concentrations of linoleic (18:2) acid. Subcutaneous AT was collected from Smith Valley Meats in Rich Creek, VA and used to prepare explants cultured in treatment media for 24 h. Treatments consisted of insulin at 0, 7, 14, and 21 nM; stearic (18:0), oleic (18:1), linoleic (18:2), and linolenic (18:3) acids at 100 μM; and linoleic (18:2) acid at concentrations of 0, 25, 50, 75, and 100 μM. Tissue explant homogenates were used for Western blotting to detect SCD1. In the first study, we found that SCD1 protein was detectable in subcutaneous AT, perirenal AT, and omental AT; however, it was not detectable in liver or small intestine samples. Also, the HPHF+ diet increased SCD1 protein expression in subcutaneous AT and perireanl AT. In the second study, SCD1 protein expression increased linearly with insulin concentration. There was no fatty acid treatment effect, but there was a negative linear effect with increase in degree of unsaturation. Finally, there was no effect on SCD1 protein expression with linoleic acid increasing in concentration. In conclusion, results indicate that SCD1 protein expression was detected in bovine AT depots, regulated by dietary fat, insulin, and by PUFA . / Master of Science

Kapsaicinoider är ämnen som finns i chilifrukterna och har på senaste tiden fått intresse som läkemedel på grund av sina analgetiska, anti-inflammatoriska och anti-cancer egenskaper. Ett nytt tillvägagångssätt att producera kapsaicinoider kan vara syntesen i rekombinant Saccharomyces cerevisiae med hjälp av metabolisk engineering och rekombinant DNA-tekniker. Gener från Capsicum chinensis, som kodar för enzymerna capsaicinoid-syntas (CS) och acyl-CoA-syntas (ACS), integrerades i S. cerevisiae i tidigare projekt. Den kända laboratoriesträngen CEN.PK modifierades med plasmidtransformation och för vildtyp-stammen ERF 5273 användes den nya CRISPR/Cas9-tekniken. Syftet med detta projekt är att ytterligare karakterisera och jämföra dessa tidigare konstruerade stammar angående deras förmåga att producera nonivamid eller andra jästspecifika kapsaicinoider. Vidare undersöks huruvida kapsaicinoider utsöndras i odlings-medium eller om de ackumuleras intracellulärt. Stammarna odlades i en bioreaktor i lite laboratorieskala. Som odlingsmedium används ett definierat medium med eller utan tillsatser. Odlings-medium kompletterades med vanillyl-amin och nonanoic acid som precursor. För att identifiera de kapsaicinoid-producerande stammarna extraherades supernatanten och cellpelleten och analyserades kromatografisk med HPLC. Resultaten från denna studie visade att jäststammarna, som innehöll båda generna (ACS + CS), sannolikt producerade nonivamid om de odlades i kompletterat medium. Vidare observerades bildning av nonivamid som ackumulerades i själva cellen. Möjligtvis producerades också jästspecifika kapsaicinoider, men topphöjden är nästan inte mätbar. Därför måste dessa resultat bekräftas ytterligare. Framtida arbeten behövs för att säkerställa och förbättra produktionen av kapsaicinoider. Keywords: acyl-CoA syntas, kapsaicinoider, kapsaicinoid syntas, metabolisk engineering, Saccharomyces cerevisiae, nonivamide / Capsaicinoids are compounds found in chili plants and have recently gained interest as pharmaceuticals due to their analgesic, anti-inflammatory and anti-cancer properties. A novel approach producing capsaicinoids could be synthesis in recombinant Saccharomyces cerevisiae with help of metabolic engineering. Genes from Capsicum chinensis, encoding the enzymes capsaicinoid synthase (CS) and acyl-CoA synthase (ACS), were previously inserted into S. cerevisiae. The known laboratory stain CEN.PK was modified with plasmid transformation and the novel CRISPR/Cas9 technology was used for the wild type strain ERF 5273. The aim of this project is to further characterize and compare these previously constructed strains concerning their ability to produce nonivamide or yeast specific capsaicinoids. Furthermore, it is examined whether capsaicinoids are excreted into the broth or accumulated intracellularly. Four different strains were cultivated in bench-scale bioreactors using medium supplemented with or without different precursors (vanillylamine and nonanoic acid). Culture broth supernatants and cell pellets were extracted and analyzed by HPLC in order to identify the capsaicinoid-producing strains. The results from this study revealed that the yeast strains harbouring both genes (ACS+CS) produced most likely nonivamide if they were cultivated in media supplemented with both precursors. Nonivamide formation was equally observed in broth supernatant and cell pellet. Additionally it was shown that yeast specific capsaicinoid production occured, althoug the peak height was close to the limit of detection and these results have to be confirmed further. Future work needs to be done in order to ensure and improve capsaicinoid production. Keywords: acyl-CoA synthase, capsaicinoids, capsaicinoid synthase, metabolic engineering, Saccharomyces cerevisiae, nonivamide.

Le projet de recherche qui constitue ce mémoire de maîtrise avait pour but d’investiguer les mécanismes physiologiques responsables de l’effet divergent de deux statines [inhibiteurs de la 3-hydroxy-3-méthylglutaryl coenzyme A (HMG-CoA) réductase] largement utilisées en clinique, la simvastatine et l’atorvastatine, sur les concentrations de cholestérol associées aux lipoprotéines de haute densité (HDL-C). Pour ce faire, nous avons comparé l’impact de ces deux médicaments hypocholestérolémiants sur la cinétique de l’apolipoprotéine A-I, la protéine majeure des lipoprotéines de haute densité, chez 7 sujets hypercholestérolémiques avec des concentrations relativement faibles de cholestérol HDL. Tous les sujets étaient soumis à chacun des deux traitements à l’étude, soit simvastatine 80 mg/jour et atorvastatine 40 mg/jour, selon un devis expérimental randomisé, en chassé-croisé et à double insu. Chaque phase de traitement durait 8 semaines. Des analyses de cinétique étaient réalisées à la fin de chacune des phases de traitement. Celles-ci ont démontré qu’un traitement de 8 semaines sous simvastatine 80 mg/jour était associé à une concentration d’apolipoprotéine A-I en circulation significativement plus élevée de 8% que sous traitement à l’atorvastatine 40 mg/jour. La concentration supérieure d’apolipoprotéine A-I sous traitement à la simvastatine était attribuable à un taux de production de d’apolipoprotéine A-I significativement plus élevé (15%) comparativement au traitement à l’atorvastatine. / The purpose of the following study was to investigate the physiological mechanisms underlying the diverging impact of two statins (HMG-CoA reductase inhibitors) widely used in clinic, simvastatin and atorvastatin, on high density lipoprotein cholesterol (HDL-C). To do so, we compared the impact of the two lipid-lowering agents on apoA-I kinetics, the protein moiety of HDL, in 7 hypercholesterolemic men with low HDL levels. All subjects were assigned two both treatments, simvastatin 80 mg/day and atorvastatin 40mg/day, in a randomized, cross-over, double-blind fashion. Each treatment phase last 8 weeks and kinetic studies were performed at the end of each treatment phase. Our analysis has demonstrated that simvastatin 80 mg/day was associated with a significant 8% greater apoA-I concentration in circulation compared to atorvastatin 40 mg/day. The higher apoA-I conentration observed with simvastatin 80 mg/day was explained by a significant 15% greater aspoA-I production rate with simvastatin 80 mg/day compared to atorvastatin 40 mg/day.

L’objectif de ces travaux de thèse était de rechercher un potentiel effet inhibiteur de l’acide acétique endogène sur le métabolisme oxydo réductif de Saccharomyces cerevisiae, afin d’évaluer la pertinence d’une stratégie d’amélioration des capacités de production d’éthanol par la modulation de la synthèse de cet acide. Ces travaux devaient également permettre d’approfondir la compréhension des principaux facteurs commandant la synthèse de l’acide acétique et plus largement des acides organiques. La stratégie de modulation de la synthèse d’acide acétique mise en place reposait sur des approches microbiologique et génétique, consistant en l’ajout d’acide oléique et / ou de carnitine dans le milieu de culture ainsi que la surexpression du gène CIT2 ou la suppression du gène ALD6.Cette démarche a permis de montrer que, contrairement à la version exogène, l’acide acétique endogène ne présentait pas d’effet inhibiteur du métabolisme oxydo réductif de Saccharomyces cerevisiae ou qu’il était négligeable par rapport au stress éthanol. En outre, la modulation de la production de cet acide ne semble pas être une stratégie envisageable en vue de l’amélioration des capacités de production d’éthanol de cette levure, bien qu’une corrélation ait été observée entre les titres finaux de ces deux molécules.En outre, il a été montré que l’isoforme 6 de l’acétaldéhyde déshydrogénase (Ald6p) était essentiel pour assurer la croissance cellulaire normale ainsi que les mécanismes de résistance au stress éthanol dans ces conditions de culture. Plus largement, l’interrelation entre les différents isoformes ne paraissait pas aussi flexible qu’en anaérobiose. Saccharomyces cerevisiae semblait également présenter un métabolisme flexible en réponse à une modulation de la synthèse d’acide acétique. La voie des pentoses phosphates serait ainsi capable de prendre le relais de l’Ald6p pour assurer la régénération du NADPH cytosolique, bien que le flux à travers cette voie semble avoir été limité par le ratio NADP+ / NADPH. Enfin, les cellules paraissaient capables de réguler la synthèse de l’acétyl coA à partir d’acide acétique en réaction à une évolution des besoins anaboliques lors de la fin de la phase de croissance. Elles seraient toutefois incapables de pallier le manque d’acétyl coA suite à la suppression du gène ALD6. La modulation de la synthèse des acides pyruvique et succinique a également fait l’objet de discussions. / The aim of this work was to investigate a potential inhibitory effect of endogenous acetic acid on the oxido-reductive metabolism of Saccharomyces cerevisiae, to assess the relevance of a strategy based of the modulation of the synthesis of this acid, to improve ethanol production capacities. This work should also help to broaden the understanding of the main factors controlling the synthesis of acetic acid, and more generally organic acids. The strategy to modulate the synthesis of acetic acid was based on microbiological and genetic approaches, consisting in the addition of oleic acid and / or carnitine in the medium as well as the overexpression of the gene CIT2 or the deletion of the gene ALD6.This approach has shown that, contrary to exogenous version, endogenous acetic acid did not induce inhibitory effects on the oxido-reductive metabolism of Saccharomyces cerevisiae, or was negligible compared to stress caused by ethanol. Moreover, the modulation of the synthesis of this acid appear to be not an attractive strategy to improve ethanol production capacities of the yeast, although a correlation was observed between the end-culture titer of these two molecules.In addition, it has been shown that the isoform 6 of acetaldehyde dehydrogenase (Ald6p) was essential to ensure regular growth and mechanisms of ethanol stress resistance under these conditions of culture. More broadly, the interrelation between the different isoforms did not seem as flexible as under anaerobic conditions. Saccharomyces cerevisiae also seemed to have a flexible metabolism in response to a modulation of the synthesis of acetic acid. The pentose-phosphate way would be able to take over from Ald6p for regeneration of cytosolic NADPH, although the ratio NADP+ / NADPH seemed to lessen the flux through this pathway. Finally, the cells appeared to be able to regulate the synthesis of acetyl-CoA from acetic acid in response to changing in anabolic needs at the end of the growth phase. However, yeasts would be unable to overcome the lack of acetyl-CoA following the suppression of the gene ALD6. The modulation of the synthesis of pyruvic and succinic acids has also been discussed.

Introdução: A associação de uma estatina com ezetimiba é tão eficaz quanto altas doses da mesma estatina na redução do LDL-colesterol. Os efeitos que não dependem dessa redução são chamados de pleiotrópicos, entre os quais podemos citar: melhora da função endotelial, efeitos anti-oxidantes, efeitos anti- inflamatórios, entre outros. Objetivo: comparar a ação de dois esquemas de tratamento que obtêm reduções equivalentes de LDL-colesterol (sinvastatina 80 mg ao dia e associação sinvastatina 10mg/ezetimiba 10 mg ao dia), sobre os efeitos pleiotrópicos: inflamação, função endotelial e oxidação da LDL. Métodos: estudamos 23 pacientes randomizados e na forma de cross-over 2x2. A inflamação foi mensurada através da PCR-us, a função endotelial por meio de ultra-sonografia e a oxidação de LDL pelas dosagens de LDL eletronegativa (LDL-) e do anticorpo anti-LDL-. Resultados: A redução do LDL-colesterol foi similar nos dois grupos (45,27% no grupo sinvastatina/ezetimiba (p<0,001) e 49,05% no grupo sinvastatina (p<0,001), sem diferença entre os tratamentos (p=0,968)). Os dois grupos apresentaram melhora da função endotelial (3,61% no grupo sinvastatina/ezetimiba (p=0,003) e 5,08% no grupo sinvastatina (p<0,001), não houve diferença entre os tratamentos (p=0,291)). Houve melhora nos níveis da PCR-us (redução de -22,8% no grupo sinvastatina/ezetimiba (p=0,004) e de 29,69% no grupo sinvastatina (p=0,01), sem diferenças entre os tratamentos (p=0,380)). Não houve redução significativa da LDL-. Ocorreu aumento na concentração do anticorpo anti-LDL eletronegativa apenas no grupo sinvastatina (p=0,045). Conclusões: as duas formas de tratamento são eficazes na melhora da função endotelial e dos níveis de PCR-us. Somente com o uso da sinvastatina em alta dose houve aumento nos níveis de anticorpos anti-LDL-. / Introduction: The co-administration of a statin with ezetimibe is as effective as high doses of the same statin in the reduction of the LDL-cholesterol. The effects which don´t depend of this reduction are called pleiotropic effects, some among them can be cited: endothelial function improvement, antioxidative and anti-inflammatory effects. Objective: compare the effectiveness of these two different treatments that obtain equivalent reductions of LDLcholesterol (simvastatin 80 mg once a day and co-administration of simvastatin 10 mg once a day and ezetimibe 10 mg once a day), about pleiotropic effects: inflammation, endothelial function and LDL oxidation. Methods: we have studied 23 randomized patients in a 2x2 cross-over study. Inflammation was measured by high-sensitive C reactive protein, endothelial function by echocardiography and LDL oxidation by electronegative LDL and electronegative anti-LDL antibodies levels. Results: the LDL-cholesterol was similar between the two groups (45,27% reduction in the simvastatin/ezetimibe group (p<0,001) and 49,05% reduction in the simvastatin group (p<0,001); no difference between treatments was found (p=0,968). The two groups had improvement in endothelial function (3,61% in the simvastatin/ezetimibe group (p=0,003) and 5,08% in the simvastatin group (p<0,001)), no differences was found between the two groups (p=0,291). High-sensitive C reactive protein had a 22,8% reduction in the simvastatin/ezetimiba group (p=0,004) and 29,69% reduction in the simvastatin group (p=0,01), with no significative difference in any of the two treatments (p=0,380). There was no significative difference in LDL- levels. The anti-LDL- antibodies concentration was increased only in the simvastatin group (p=0,045). Conclusion: the two forms of treatments presented some similar pleiotropic effects - improvement in endothelial function and decreased hs-CRP levels. Only with a high simvastatim dose the anti-LDL- antibodies concentration was increased.

HMG-CoA-Reduktasehemmer, sogenannte Statine, und regelmäßige körperliche Aktivität sind mit vermindertem Auftreten zerebrovaskulärer Ereignisse und Zunahme der endothelialen Stickstoffmonoxidsynthase (eNOS) assoziiert. Die Erhöhung der eNOS-mRNA ist mit verbessertem zerebralen Blutfluß und Neuroprotektion bei einer zerebralen Ischämie verbunden. Vor dem Hintergrund, daß Thrombosen und Thrombembolien die häufigste Ursache zerebro- und kardiovaskulärer Ereignisse darstellen, sind NO-vermittelte antithrombotische Effekte jedoch kaum untersucht. Ebenso wenig ist über mögliche Absetzeffekte nach Beendigung einer Statintherapie bekannt. Daher untersuchten wir, ob die Statine Atorva- und Rosuvastatin eNOS-abhängig zu Neuroprotektion führen und verglichen die Effekte mit einem zweiten eNOS-regulierenden Mechanismus: der regelmäßigen körperlichen Aktivität. Dazu quantifizierten wir nach entsprechender Vorbehandlung eNOS auf mRNA- und Proteinebene aus Aorten, Hirngewebe sowie Thrombozyten und bestimmten die Läsionsvolumina im experimentellen Schlaganfallmodell. Außerdem untersuchten wir nach Statingabe Thrombozytenfunktionsparameter sowie Blutungszeit und Thrombusformation in vivo. Zwei bzw. vier Tage nach Absetzen der Statinbehandlung wiederholten wir die eNOS-Messungen, Schlaganfallexperimente und Gerinnungsanalysen. Wir fanden nach Statinvorbehandlung cholesterinunabhängig eine Zunahme der eNOS, was mit Neuroprotektion im Schlaganfallmodell und verminderter Gerinnungsaktivität verbunden war. Nach Absetzen der Behandlung kam es jedoch zu einer drastischen Abnahme der eNOS, was mit deutlichem Anstieg der Thrombozytenmarker im Plasma und schnellem Verlust der beobachteten positiven Effekte auf Läsionsgröße und Gerinnungssystem einherging. Regelmäßige körperliche Aktivität führt ebenfalls eNOS-abhängig zu verbessertem zerebralen Blutfluß und kleineren Läsionsvolumina bei zerebraler Ischämie. Diese Ergebnisse sind mit den Daten nach Statingabe vergleichbar. Wir demonstrieren einen Klasseneffekt der Statine für eNOS-vermittelte Neuroprotektion im zerebralen Ischämiemodell. Durch die zusätzliche gerinnungshemmende Wirkung könnte diese Wirkstoffklasse neue Ansätze zur prophylaktischen Schlaganfallbehandlung unabhängig vom Cholesterinspiegel eröffnen. Ein Absetzen der Statinbehandlung kann jedoch zu einer Zunahme der Schlaganfallgröße führen und sollte möglicherweise bei Risikopatienten vermieden werden. Regelmäßiges körperliches Training führt zu vergleichbarer Erhöhung der eNOS sowie Neuroprotektion und bietet damit eine sinnvolle Verknüpfung aus prophylaktischer Schlaganfallbehandlung und Rehabilitation. / HMG-CoA-reductase inhibitors, so called statins and regular physical activity are associated with less cerebrovascular events and increase of endothelial nitric oxide synthase (eNOS). Raise of eNOS-mRNA results in cerebral blood flow (CBF) augmentation which refers neuroprotection after ischemic stroke. It is known that thromboses cause the most cerebrovascular events, but nitric oxide (NO) dependent antithrombotic effects are poor examined. In addition there are little information about effects after withdrawal of statin treatment. That is why we investigated Atorva- and Rosuvastatin regarding eNOS dependent neuroprotection and compared the effects with regular physical activity, the second eNOS enhancing mechanism. Therefore after corresponding pretreatment we quantified eNOS-mRNA and protein from aortas, brain tissue and thrombocytes and determined lesion volume after experimental middle cerebral artery occlusion (MCAo). Furthermore after statin treatment we measured marker of thrombocyte activation, as well as bleeding time and thrombus formation in vivo. Two and four days after withdrawal of statin treatment we repeated eNOS measurements, neuroprotection studies and coagulation analyses. We found eNOS upregulation independent from serum cholesterol level after statin pretreatment and this was associated with neuroprotection after ischemic stroke and decreased platelet activation. But after withdrawal of statin treatment eNOS expression was downregulated, which went along with clear upregulation of platelet activation and a rapid loss of the observed positive effects on lesion volume and hemostasis. Regular physical activity leads to an increase of eNOS, which we could correlate with CBF augmentation and improved outcome after MCAo. These results were comparable to the data after statin treatment. We demonstrate a class effect of statins for eNOS-dependent neuroprotection in our ischemia modell. Because of the additional antithrombotic effects statins may present a new approach to prophylactic stroke treatment independent from cholesterol level. Withdrawal of statin treatment may refer increased cerebral lesion volume and should be avoided in patients with risk for cerebrovascular events. Regular physical activity results in comparable eNOS dependent neuroprotection and offers a useful combination between prophylactic stroke treatment and rehabilitation.

Die peroxisomalen ABC-Transporter Pxa1p und Pxa2p sind Halbtransporter. Genetische Studien ergaben Hinweise, dass sie zur Bildung aktiver Transporter heterodimerisieren und am Import von langkettigen Fettsäuren in die Peroxisomen von S. cerevisiae beteiligt sind. Es wurden epitopmarkierte Varianten der Proteine als Komplex isoliert. Damit wurde gezeigt, dass Pxa1p und Pxa2p ein stabiles Heterodimer bilden. Zur Charakterisierung der ATP Bindeeigenschaften wurden die Transporter mit 8-azido-[alpha-32P]-ATP inkubiert und kovalent verknüpft. Dabei konnte gezeigt werden, dass Pxa1p und Pxa2p eine unsymmetrische Bindung des ATP Analogons aufweisen. Pxa2p bindet deutlich mehr azido-ATP als Pxa1p, bei sehr ähnlichen Dissoziationskonstanten. Die reduzierte ATP Bindung von Pxa1p spiegelt sich durch degenerierte Sequenzmotive der an der ATP Bindung beteiligten Sequenzen wieder. Die isolierten ABC-Transporter wurden für ATPase Messungen eingesetzt. Sie zeigten eine basale ATPase Aktivität, die durch Zugabe langkettiger Coenzym A aktivierter Fettsäuren, wie Oleoyl-CoA und Palmitoyl-CoA stimulierbar war. Eine Lysin Mutation im Walker A Motiv von Pxa1p hatte keine Funktionalitätseinbuße zur Folge. Dieselbe Mutation bei Pxa2p führte im Wachstumstest auf Festmedium mit Ölsäure als Kohlenstoffquelle zu einem deutlich verlangsamten Wachstum. Diese Ergebnisse korrespondieren mit der beobachteten unsymmetrischen ATP Bindung von Pxa1p und Pxa2p, da bei dem schwächer bindenden Pxa1p die Mutation wirkungslos blieb. Keine Übereinstimmung war bei den ATPase Aktivitätsmessungen der aufgereinigten Mutanten zu verzeichnen. Beide Mutanten zeigten eine unbeeinträchtigte ATPase Aktivität. Die ABC-Transporter wurden in Proteoliposomen eingebaut und für Transportmessungen mit einem Spin-Label markierten Oleoyl-CoA verwendet. Die Transportmessungen zeigten einen ATP abhängigen Transport, woraus geschlossen wurde, dass Pxa1p-Pxa2p tatsächlich Coenzym A Ester langkettiger Fettsäuren transportiert. / The peroxisomal ABC-transporters Pxa1p and Pxa2p are half transporters. Previous genetic investigations have demonstrated that Pxa1p and Pxa2p have to dimerise in order to build a functional transporter, which is very likely involved in the import of long chain fatty acids into peroxisomes of S. cerevisiae. In this work, tagged versions of the proteins were purified as a complex. This proved for the building of a stable hetero dimer. For characterisation of the ATP binding properties, the transporters were incubated and cross linked with 8-azido-[alpha-32P]-ATP. This revealed an asymmetric binding of the ATP analogue. Pxa2p binds much more azido-ATP, than Pxa1p, while the dissociation constants are rather similar. The poorer ATP binding of Pxa1p is reflected by degenerated sequence motifs in the nucleotide binding fold. The purified ABC-transporters have been used for ATPase assays. They showed a basal ATPase activity, which could be stimulated by addition of long chain fatty acid CoAs, like oleoyl-CoA and palmitoyl-CoA. Mutants with a lysine mutation in the walker A motive of Pxa1p led to no functional impairment, while the corresponding lysine mutation in Pxa2p led to reduced growth on agar plates with oleic acid as sole carbon source. The result corresponds with the ATP binding properties of Pxa1p. Because of the poorer ATP binding, even in the wild type protein, the mutation was not supposed to have a big influence. No accordance was found in respect to the ATPase measurements of the isolated mutant proteins. Both mutants revealed unaffected ATPase activity. The purified ABC-transporters were reconstituted in proteoliposomes and used for translocation assays of a spin-labelled oleoyl-CoA derivative. The measurements revealed an ATP dependent transport of the oleoyl-CoA analogue. This led to the conclusion, that Pxa1p-Pxa2p is indeed the transporter of long chain acetyl CoA esters, which were transported in an ATP dependent manner.

Introdução: As avaliações econômicas completas do tipo custo-utilidade, suportadas por dados de efetividade do mundo real, permitem uma perspectiva diferenciada da avaliação de tecnologia em saúde. Objetivo: Realizar uma análise de custo-utilidade do uso de estatinas para a prevenção secundária de eventos cardiovasculares em portadores de doença cardiovascular isquêmica, e avaliar a variabilidade da efetividade e da razão de custo-efetividade incremental com diferentes classificações de usuários de estatina (incidentes e prevalentes). Método: Um modelo de microssimulação de Markov com 5 estados, ciclos anuais e horizonte temporal de 20 anos, com taxas de desconto de 5% foi desenvolvido. As probabilidades de transição para mortalidade por todas as causas foram extraídas após pareamento por escore de propensão dos dados e tratamento de dados ausentes de uma base secundária de registro assistencial com linkage determinístico com a base de mortalidade do Ministério da Saúde. As probabilidades dos desfechos não-fatais foram obtidas na literatura. As medidas de efetividade (QALY) foram calculadas com dados publicados dos domínios do SF-36 de um estudo realizado com a população do mesmo hospital, no mesmo período e com as mesmas condições clínicas e transformados em medidas de utilidade por modelo validado. Somente custos diretos na perspectiva do reembolso do SUS foram considerados. Resultados: 3.150 pacientes foram pareados após o escore de propensão, 1.050 não usuários de estatina, 1.050 usuários de estatinas classificados como prevalentes e 1.050 usuários de estatinas classificados como incidentes, com diagnóstico de doença cardiovascular isquêmica prévia, com seguimento médio de 5,1 anos. A efetividade das estatinas quando considerados todos os usuários em relação aos não usuários resultou em um HR para mortalidade de 0,992 (IC 95% 0,85; 0,96) e de 0,90 (IC 95% 0,85; 0,96) para os usuários incidentes. A RCEI comparando todos os usuários de estatinas versus não usuários foi de R$5.846,10/QALY e de R$7.275,61/QALY para os usuários incidentes. Conclusão: As estatinas diminuíram a mortalidade por todas as causas, e a análise incluindo usuários prevalentes diminui o tamanho do efeito. O tratamento possui custo-efetividade favorável dentro do limiar de disponibilidade a pagar definido, sendo modificado pela forma de extração do dado de efetividade / Background: The complete economic evaluations, such as cost-utility analysis, supported by real world data of effectiveness lead to a more realistic perspective of a health technology assessment. Objective: Perform a cost-utility analysis of statins for secondary prevention in ischemic cardiovascular disease patients based on effectiveness from real world data and evaluate the variability of effectiveness and incremental cost-effectiveness ratio (ICER) considering prevalent and incident users. Methods: A Markov microssimulation model with five states, annual cycle and time horizon (TH) of 20 years, with discount rate of 5% was developed. Transition probabilities for all cause mortality was derived from a secondary database of a teaching hospital after record linkage with national registry of mortality database and an analysis of propensity score matching and multiple imputation analysis for missing data. Non-fatal endpoints were derived from a published meta-analysis. Utility measures was calculated with a validated model to derive values from published domains of SF-36 QoL questionnaire, domains was measured for a published RCT in the same teaching hospital, over the same period, with similar age and diagnostic characteristics. Only direct costs were analyzed from the Brazilian public health reimbursement perspective. Results: 3150 patients were matched, 1050 non-statins users (CG), 1050 prevalent statins users (PSU) and 1050 incident statins users (ISU) with previous cardiovascular disease, with mean follow-up of 5,1 years. Treatment effects on the treatment group considering all statins users for all cause mortality had a hazard ratio of HR:0,992 (IC 95% 0,85 - 0,96) and HR: 0,90 (IC 95% 0,85 - 0,96) only for ISU. The ICER comparing all users with non-users was R$5.846,10 per QALY and for ISU was R$7.275,61 per QALY. Conclusion: Real world evidence demonstrated that statins are an effective treatment to reduce all cause mortality in secondary prevention and are a cost-effective strategy considering the willingness to pay established, but the prevalent users resulted in less effectiveness of the drug when included in the analysis and influenced the ICER

Diversos estudos epidemiológicos mostram que nutrientes e outros compostos bioativos presentes nos alimentos (CBA) apresentam atividade quimiopreventiva contra o câncer. Assim, destaca-se o estudo dos isoprenóides devido a sua ação promissora tanto na prevenção quanto na terapia do câncer. Todavia, apesar dessas evidências, pouco se sabe a respeito da ação dessas substâncias nos processos de proliferação celular e apoptose in vivo. Assim, 141 ratos Wistar foram tratados durante duas semanas consecutivas com farnesol (grupo FR, 25 mg/100 g de peso corporal) ou óleo de milho (grupo OM; controle, 0,25 mL/100 g de peso corporal) e sacrificados em diferentes momentos após a hepatectomia parcial (HP; 0 h, 30 min, 2 h, 4 h, 8 h, 12 h, 18 h e 24 h). Os parâmetros hepáticos analisados foram a proliferação celular (núcleos marcados para PCNA/mm2), apoptose (corpúsculos apoptóticos [CA\'s] por mm2) e expressão de p65, ciclina D1 (\"western blot\") e HMG-CoA redutase (\"dot-blot\"). Os animais tratados com o isoprenóide, assim como o grupo controle, apresentaram reduzida taxa de proliferação celular até 8h após a cirurgia. No entanto, a partir desse momento, o grupo FR passou a apresentar taxa de proliferação celular inferior ao grupo OM, diferença esta que atingiu significância estatística (p<0,05) 24h após a HP. Com relação a apoptose, animais tratados com FR apresentaram maior número de CA\'s (p<0,05) do que o grupo OM 30 min após a HP. Já em relação à ação do FR em âmbito molecular, houve uma redução de 40% e 50% na expressão de p65 e ciclina D1 30min e 24h após a HP, respectivamente, embora essas diferenças não tenham atingido significância estatística (p>0,05). Além disso, animais tratados com o isoprenóide apresentaram maior (p<0,05) expressão do gene que codifica para HMG-CoA redutase 2 h e 12 h após a cirurgia. Assim, tanto a inibição da proliferação celular quanto a indução de apoptose podem ser reflexo das alterações da expressão hepática dos genes para HMG-CoA redutase, p65 e ciclina D1 por parte do isoprenóide. / Epidemiological data have shown that nutrients and others bioactive compounds in food have chemopreventive activities against cancer. Among these compounds, isoprenoids are suggested either as a chemopreventive or chemotherapy agents. However, despite these evidences, studies focused on the isoprenoids activities on cell proliferation and apoptosis in vivo are rare. Thus, the effect of the 15-carbon isoprenoid farnesol on liver regeneration after partial hepatectomy was evaluated. Wistar rats were treated for two consecutive weeks with farnesol (FR group, 25 mg/100 g body weight) or corn oil (OM group, control, 0,25 mL/100 g body weight) and killed at different time points after partial hepatectomy (HP; 0 h, 30 min, 2 h, 4 h, 8 h, 12 h, 18 h and 24 h). Still, hepatic cell proliferation (PCNA lebeled nuclei), apoptosis (quantification of apoptotic bodies), p65 and cyclin D1 protein expression (western blot) and HMG-CoA reductase mRNA expression (dot blot) were also evaluated. Comparing to OM group, farnesol treatment significantly inhibited (p<0,05) hepatic cell proliferation 24 h after HP. Regarding apoptosis, also compared to controls, farnesol treated rats presented more (p<0,05) apoptotic bodies at 30 min. Besides, there were a suggestion of a higher number of apoptotic bodies 2 and 12 hours after HP in FR group comparing to OM group. According to western blot analysis, comparing to controls, this 15-carbon isoprenoid reduced 40% and 50% p65 and cyclin D1 hepatic protein expression, 30 min and 24 h after partial hepatectomy, respectively, although the differences did not also reach the statistical significance. Furthermore, farnesol treated rats had higher (p<0,05) HMG-CoA reductase mRNA levels than controls 2 h and 12 h after the surgery. Theses data suggest that the alterations on p65, cyclin D1 and HMG¬-CoA reductase gene expression observed in FR group might be associated with the inhibition of cell proliferation and the induction of apoptosis by farnesol.

Le contexte de ce projet de thèse était d’approfondir la compréhension du métabolisme de Trypanosoma brucei. Les trypanosomes utilisent différents types de sources de carbone, des hydrates de carbone ainsi que des acides aminés pour alimenter leurs besoins énergétiques et biosynthétiques (conditions imitant réellement l'environnement dans la mouche tse-tse). Les différences de thioesters d'acyl-CoA sont encore inconnues dans ces conditions. Une telle élucidation est essentielle pour comprendre les adaptations métaboliques de l'organisme au cours de son cycle de vie. Cet objectif pourrait être complété par une combinaison d'analyses sensibles de divers groupes de métabolites, de délétions dirigées de gènes ou de régulations négatives. Ces derniers développements intègrent un flux de travail complet d'analyse des flux métaboliques par 13C à l’état-instationnaire. Ce flux de travail combine les méthodes existantes pour la collecte d'échantillons, la métabolomique quantitative basée sur MS et l'analyse isotopique d'acides organiques, d'acides aminés, de composés phosphorylés en plus des thioesters d'acyl Coenzyme A (acyl-CoAs), qui représentent un point central entre le métabolisme central du carbone et les voies anaboliques. Ce flux de travail a d'abord été évalué et validé sur l'organisme modèle Escherichia coli et a fourni de nouvelles idées sur son fonctionnement métabolique. Par la suite, ce flux de travail a ensuite été exploité pour étudier le métabolisme de T. brucei, pour lequel les résultats préliminaires sont décrits et discutés dans cette thèse. / Unusual metabolism of protozoan parasite causing deadly sleeping sickness, Trypanosoma brucei, has been enigmatic for many years. In the past decades, targeted genetic perturbations combined with metabolic analysis have advanced the view on complex compartmentalized metabolism of this organism, but acyl-CoA metabolism on the crossroad between catabolic and anabolic pathways, remains largely uncharacterized. Present work aims at clarifying mitochondrial operation and topology of acyl-CoA network of T. brucei, as well as its interconnections with the rest of metabolism. This has required the development of a complete framework for investigation of acyl-CoA metabolism in T. brucei integrating isotope labeling experiments with metabolite quantification. Sensitive LC-MS method for identification and quantification of acyl-CoAs based on high-resolution mass spectrometry (HRMS) with LTQ-OrbiTrap has been established and applied to investigate acyl-CoA metabolism in the protozoan parasite, as well as in the model organism in systems and synthetic biology, Escherichia coli. Complete workflow from cell cultivation, measurement of extracellular fluxes and analysis of isotopic profile which is result of enzyme-specific incorporation of isotopic tracer allowed modelling of metabolic network and calculation of metabolic fluxes. The entire workflow has been biologically validated and has clarified the link between acyl-CoA and central carbon metabolism in E. coli. The proposed framework has been adapted to T. brucei, for which several sample collection methods have been evaluated thoroughly. It was possible to extract, identify and quantify main acyl-CoA species produced from glucose catabolism. This optimised setup for acyl-CoA analysis will allow collection of data for NMR-based analysis of metabolic end products as well as collection of intracellular metabolites from same sample.